Company / Operating Cash Flow per Share
Vivos Therapeutics, Inc. Operating Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.15
FY2025
5-year range
-$21.28 / -$0.31
FY2021-FY2025
Trend
+66.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-21.28 to $-2.15 over the past 2 years.
Based on SEC 10-K filings.
-2.15 in FY2025.
Improved from $-21.28 to $-2.15 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 66.9% year-over-year.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.15 | +66.9% |
| FY2024 | -$6.51 | +69.4% |
| FY2023 | -$21.28 | -3011.6% |
| FY2022 | -$0.68 | -119.2% |
| FY2021 | -$0.31 | +27.3% |
| FY2020 | -$0.43 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026